SCHEDULE: RA Capital Management Files Schedule 13G Amendment

RA Capital Management, L.P. and related entities have filed an amendment to their Schedule 13G, reporting zero beneficial ownership of Fulcrum Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• This filing is an amendment to a Schedule 13G, which reports beneficial ownership of securities.
• The reporting persons are RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P.
• As of June 30, 2026, the reporting persons collectively beneficially owned 0.00 shares of Fulcrum Therapeutics, Inc. common stock.
• This represents 0.0% of the class of securities.
• The filing explicitly states that the reporting persons expressly disclaim status as a 'group' for purposes of this Schedule 13G/A.
• The filing certifies that the securities were not acquired or held for the purpose of or with the effect of changing or influencing control of the issuer.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update regarding beneficial ownership, with no new financial or strategic information.

Positives

• The filing confirms that RA Capital Management and its affiliates no longer hold any beneficial ownership in Fulcrum Therapeutics, Inc. common stock.
• This could indicate a strategic shift or reallocation of capital by RA Capital Management.

Negatives

• The filing indicates a complete divestment or lack of prior ownership by a significant investment entity, which could be interpreted negatively by the market if RA Capital was previously a notable holder.
• The aggregate amount beneficially owned by each reporting person is 0.00 shares, with 0.0% of the class represented.

Risks

• The absence of beneficial ownership by RA Capital Management could signal a lack of confidence in Fulcrum Therapeutics' future prospects from a major institutional investor.
• Market participants may interpret this as a negative signal, potentially impacting the stock price.

Future Outlook

No forward-looking statements or guidance are provided in this filing, as it solely concerns beneficial ownership reporting.

Management Comments

• The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G/A.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors. A complete reduction in beneficial ownership to zero by a known investment firm like RA Capital Management, especially if they were previously a significant holder, can be a signal to the market, though the reasons are not detailed in this specific filing.

Comparison to Industry Standards

• Schedule 13G filings are standard for passive investors holding more than 5% of a company's stock.
• The reporting of zero beneficial ownership is a specific outcome for RA Capital Management and its affiliates concerning Fulcrum Therapeutics, Inc. on this particular date.

Stakeholder Impact

• Shareholders may interpret the lack of ownership by RA Capital Management as a potential negative signal, possibly affecting stock sentiment.
• The market may react to the absence of a previously known significant holder.

Next Steps

• No specific next steps are outlined in this filing beyond the reporting requirement itself.

Key Dates

Keywords

Beneficial Ownership, Schedule 13G, RA Capital Management, Fulcrum Therapeutics, Securities Ownership, Investment Management, Divestment